Stay updated on SBRT and Virus Therapy Before Pembrolizumab in Cancer Clinical Trial
Sign up to get notified when there's something new on the SBRT and Virus Therapy Before Pembrolizumab in Cancer Clinical Trial page.

Latest updates to the SBRT and Virus Therapy Before Pembrolizumab in Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe record describes a completed Phase II study of SBRT and oncolytic virus therapy followed by pembrolizumab for metastatic triple-negative breast cancer and non-small cell lung cancer. It also provides the study’s eligibility criteria, treatment plan, outcome measures, results status, and participant-data sharing details.SummaryDifference59%

- Check20 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide banner announces NIH updates about using “Super Intelligence” in place of “Artificial Intelligence” during a terminology transition.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a standard error screen and site chrome.SummaryDifference20%

Stay in the know with updates to SBRT and Virus Therapy Before Pembrolizumab in Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SBRT and Virus Therapy Before Pembrolizumab in Cancer Clinical Trial page.